Value
5.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 9.0 |
OABI · Why this verdict
Why OmniAb (OABI) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score5.4/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
OmniAb is a speculative, cash-burning biotechnology platform whose losses are narrowing and whose recent earnings beats and revenue rebound support the story, but low business quality and binary industry risk keep it from earning a position.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Business quality is below average at 4.6, with cash burn and an operating margin of -49.5% flagged as value-trap signals. Bear case | Operating margin improves from -49.5% toward breakeven and free cash flow burn does not widen. | ↓Deteriorating |
| CounterThe Rule of 40 reading of 243 is rated elite and the current ratio is strong, so liquidity may fund the burn for a long time. | ||
Quarterly losses per share are narrowing, with the last two reported quarters beating estimates (-0.05 vs -0.13 and -0.06 vs -0.10). Earnings | EPS losses stay narrower than -0.10 per quarter and beats continue through the next four reports. | ↓Deteriorating |
| CounterEarnings are lumpy and one quarter missed (-0.11 vs -0.09); the beats may reflect timing of milestone revenue rather than durable improvement. | ||
Quarterly revenue rebounded to $13.4M and $14.4M in the last two quarters from $2.2M in the September 2025 quarter, showing the revenue base can scale. Revenue quarters | Quarterly revenue holds above $8M on a trailing basis over the next 12 months. | ↓Deteriorating |
| CounterRevenue swings widely (from $2.2M to $14.4M within two quarters), so the rebound may be milestone timing and not recurring. | ||
The price of $4.87 sits 50.1% below the analyst-derived take-profit of $7.31, but the industry is treated as binary and the position size recommendation is to avoid. Bull case | Price moves toward the $7.31 analyst target without breaching the $4.53 stop. | →Stable |
| CounterAnalyst targets in biotechnology are often stale or haircut, and implied volatility of 116% means the stop can be hit quickly. | ||
Momentum is constructive: rising on-balance volume, price above the 200-day average and institutions accumulating. Momentum breakdown | Price stays above its 200-day average and momentum stays at or above 5.5 over the next two quarters. | ↑Improving |
| CounterChart signals are described as mixed with no clear pattern, and thin option open interest makes the technical read unreliable. | ||
Business quality is below average at 4.6, with cash burn and an operating margin of -49.5% flagged as value-trap signals.
↓DeterioratingBear case
- Expectation
- Operating margin improves from -49.5% toward breakeven and free cash flow burn does not widen.
CounterThe Rule of 40 reading of 243 is rated elite and the current ratio is strong, so liquidity may fund the burn for a long time.
Quarterly losses per share are narrowing, with the last two reported quarters beating estimates (-0.05 vs -0.13 and -0.06 vs -0.10).
↓DeterioratingEarnings
- Expectation
- EPS losses stay narrower than -0.10 per quarter and beats continue through the next four reports.
CounterEarnings are lumpy and one quarter missed (-0.11 vs -0.09); the beats may reflect timing of milestone revenue rather than durable improvement.
Quarterly revenue rebounded to $13.4M and $14.4M in the last two quarters from $2.2M in the September 2025 quarter, showing the revenue base can scale.
↓DeterioratingRevenue quarters
- Expectation
- Quarterly revenue holds above $8M on a trailing basis over the next 12 months.
CounterRevenue swings widely (from $2.2M to $14.4M within two quarters), so the rebound may be milestone timing and not recurring.
The price of $4.87 sits 50.1% below the analyst-derived take-profit of $7.31, but the industry is treated as binary and the position size recommendation is to avoid.
→StableBull case
- Expectation
- Price moves toward the $7.31 analyst target without breaching the $4.53 stop.
CounterAnalyst targets in biotechnology are often stale or haircut, and implied volatility of 116% means the stop can be hit quickly.
Momentum is constructive: rising on-balance volume, price above the 200-day average and institutions accumulating.
↑ImprovingMomentum breakdown
- Expectation
- Price stays above its 200-day average and momentum stays at or above 5.5 over the next two quarters.
CounterChart signals are described as mixed with no clear pattern, and thin option open interest makes the technical read unreliable.
Per-dimension breakdown
Quality
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Current ratio | 8.2 |
| FCF quality | 0.0 |
| Moat | 7.2 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -1% of revenue
- ▸Rule of 40: 243 (elite)
Growth
5.0/10data confidence 50%Momentum
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 7.2 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.0 |
| Analyst rating | 5.0 |
| Price target | 9.7 |
- ▸Analyst upside: 57%
Insider
6.7/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.1 |
| quality rank | 3.3 |
| growth rank | 9.2 |
- ▸Industry growth leader
Technical
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.4 |
| 52w position | 9.6 |
| gap | 5.0 |
Risk (lower is worse)
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.8 |
| days to cover | 3.5 |
| volatility | 0.0 |
| put call | 6.7 |
| implied vol | 0.4 |
| max pain risk | 3.0 |
| beta | 5.5 |
| debt equity | 9.7 |
- ▸High IV: 78%
- ▸Above max pain $2
Catalyst
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Earnings in 1 day
How the verdict was assembled
Engine trigger
Earnings in 1 day. Wait until post-earnings.
Engine technical detail
verdict_path:
L3:NEWS_BLOCK|ENTRY_STICKY:WITHIN_BANDPassed (6)
- MOMENTUM:6.2>=5.5
- ASYMMETRY:2.4>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- EARNINGS_PROXIMITY:1d<=7d
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
2.42
Upside
+36.3%
Downside
15.0%
Sizing output
STARTER
SetupBreakout — Golden cross, above all MAs, RSI 63, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
A recent news event triggered an L3 news-block on the verdict path. Trigger: Earnings in 1 day. Wait until post-earnings. The 10-dimension scores remain Insider at 6.7 (strongest), but EARNINGS_PROXIMITY:1d<=7d also fails — the news block is the proximate trigger, not the sole driver.
The strongest dimensions are Insider at 6.7, Sentiment at 6.4, and Momentum at 6.2; the weakest are Technical at 3.8, Risk (lower is worse) at 4.5, and Quality at 4.6. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 2.42 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Narrowing Losses Earnings Beats
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P2Revenue Rebound Lumpy
Trip ifQuarterly revenue falls below $5M for 2 consecutive quarters.
- P3Cash Burn Low Quality
Trip ifOperating margin falls below -75% from current -49.5%.
- P4Analyst Upside Vs Binary Risk
Trip ifShare price drops to $4.53 or below, hitting the stop loss.
- P5Constructive Momentum Setup
Trip ifMomentum score falls below 4.5 from current 6.5.